Tag: news

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Flywire Corporation (NASDAQ:FLYW), Lockheed Martin Corporation (NYSE:LMT), and Sable Offshore Corporation (NYSE:SOC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

ROAD TOWN, British Virgin Islands, Aug. 11, 2025 (GLOBE NEWSWIRE) -- LYNO AI is attracting serious investor attention since its early bird presale progress is gaining momentum. With over 265,000 tokens already sold in the total allocation of 16 million tokens, the sale is already proving to be very strong in demand in the market. Investors are rushing to buy their tokens as the presale price is at the moment only 0.050 dollars per token and this phase is about to end.

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (NASDAQ:NEOG), Alto Neuroscience, Inc. (NYSE:ANRO), RxSight, Inc. (NASDAQ:RXST), and Replimune Group, Inc. (NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenhawk Resources Inc. (“Greenhawk” or the "Company") (CSE: GRHK) announces John Kennedy FitzGerald (“FitzGerald”), of Toronto, Ontario announces that on Friday, August 8, 2025 he acquired in part through the facilities of the Canadian Securities Exchange and in part through a private purchase and sale transaction, ownership and control over an aggregate of 10,233,333 common shares of the Company.

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.021 per Unit, for total gross proceeds to Revive of $60,900. Furthermore, the Company announces that it has settled an amount of $67,400 owing pursuant to an arm’s length note through the issuance of 3,209,523 Units, at a price of $0.021 per Unit, being the same issue price and security offered pursuant to the Offering.